Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Elafibranor acts as an agonist of PPAR-α and PPAR-δ and is currently under development for the treatment of NAFLD.
|
31523999 |
2020 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Then the HFD-induced NAFLD mice were treated with vitamin D. Next, the serum levels of TNF-α, GSH-px and malondialdehyde (MDA) were assessed using ELISA and ROS content was evaluated by flow cytometry, followed by the measurement of expression of Duox1, Duox2, SOD1, SOD2, PRDX1 I, ACC, SREBP1c, MTTP, PPARα, p53, p21 and p16 using RT-qPCR and Western blot analysis.
|
31756344 |
2020 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
|
31173696 |
2020 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggest that the GPS2-PPARα partnership in hepatocytes coordinates the progression of NAFLD in mice and in humans and thus might be of therapeutic interest.
|
30975991 |
2019 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The downregulation of miR-181a expression can be a therapeutic strategy for NAFLD by modulating its target PPARα.
|
30558790 |
2019 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Preventive Effects of Total Flavonoid C-Glycosides from Abrus mollis on Nonalcoholic Fatty Liver Disease through Activating the PPARα Signaling Pathway.
|
31026873 |
2019 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Improving hepatic steatosis in HHcy mice by pharmacological inhibition of sEH to activate peroxisome proliferator-activated receptor-α was ligand dependent, and sEH could be a potential therapeutic target for the treatment of nonalcoholic fatty liver disease.
|
30789748 |
2019 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, this study aimed to determine whether ascorbic acid can inhibit obesity and nonalcoholic fatty liver disease (NAFLD) in part through the actions of PPARα.
|
30283077 |
2019 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Meanwhile, the NAFLD mice were exposed to intermittent hypoxia or intermittent hypoxia with PPARα agonists.
|
31430204 |
2019 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The results revealed the potential mechanism underlying the effects of DAP on NAFLD in vitro: i) By increasing the phosphorylation of AMPK, DAP inhibited the expression of SREBP‑1C and PNPLA3, and induced that of PPARα.
|
30957185 |
2019 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, it activated transcription factor FOXO1 through post‑transcriptional regulation of the expression of PPARα and further inhibited the synthesis of TGs, thereby restraining the progression of NAFLD.
|
30664220 |
2019 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The serum effects of RBTP were: (1) decreases in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AKP), total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), D-lactate (D-LA), diamine oxidase (DAO), lipopolysaccharide (LPS), and an increase of high density lipoprotein cholesterol (HDL-C) levels; (2) a decrease of inflammatory cytokines such as interleukin 1 beta (IL-1β), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor alpha (TNF-α), and interferon gamma (INF-γ); (3) a decrease the reactive oxygen species (ROS) level in liver tissue; and (4) alleviation of pathological injuries of liver, epididymis, and small intestinal tissues caused by NAFLD and protection of body tissues. qPCR and Western blot results showed that RBTP could up-regulate the mRNA and protein expressions of LPL, PPAR-α, CYP7A1, and CPT1, and down-regulate PPAR-γ and C/EBP-α in the liver of NAFLD mice.
|
31480575 |
2019 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results may contribute to investigations on transcriptional control in hepatic physiology and underscore the clinical relevance of drugs that target PPARα in liver pathologies, such as non-alcoholic fatty liver disease.
|
28774777 |
2018 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
DNA methylation at the PPAR-α gene is involved in the pathogenesis of NAFLD and is possibly reversible by 5-Aza-CdR and curcumin.
|
29802754 |
2018 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
NaB-induced PPARα activation stimulates fatty acid β oxidation and inhibits NF-κB-mediated inflammation pathways via protein-protein interaction, thus contributing to amelioration of high-fat-diet-induced NAFLD in adult rats.
|
29961332 |
2018 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We investigated the correlation between the methylation levels of peroxisome proliferator-activated receptor-α (PPAR-α) in the peripheral blood and atherosclerosis in patients with nonalcoholic fatty liver disease (NAFLD) with diabetes mellitus (DM).
|
29456675 |
2018 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
This has important clinical implications in disease states with impaired hepatic PPARA function, such as nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.
|
30158201 |
2018 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Some new pharmacological strategies act broadly to alter energy balance or influence pathways that contribute to NAFLD (e.g., agonists for PPAR γ, PPAR α/δ, FXR and analogs for FGF-21, and GLP-1).
|
28867301 |
2018 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression of PPAR-α can be used as a new basis for the diagnosis and treatment of NAFLD complicated with DM.
|
29434731 |
2018 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There is an up-expression of PPARα target genes in the PBMCs of NAFLD patients, possibly leading to changes in β-oxidation and insulin resistance.
|
30428868 |
2018 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We identified PGC1A, PPARα, FXR, and LXR as regulatory factors that could become important in sex-dependent personalized treatment of NAFLD.
|
29706895 |
2018 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Potential involvement of PPAR α activation in diminishing the hepatoprotective effect of fenofibrate in NAFLD: Accuracy of non- invasive panel in determining the stage of liver fibrosis in rats.
|
27930988 |
2017 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pharmacological inhibition of PARP1 may alleviate PPARα suppression and therefore have therapeutic potential for NAFLD.
|
27979751 |
2017 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The efficacy of peroxisome proliferator-activated receptor α-agonists (e.g., fibrates) against nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) in humans is not known.
|
28195199 |
2017 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hydrogen-rich saline improves non‑alcoholic fatty liver disease by alleviating oxidative stress and activating hepatic PPARα and PPARγ.
|
28098910 |
2017 |